Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: Findings from the Dallas Heart Study

Clinical Chemistry

Volumn 54, Issue 12, 2008, Pages 1975-1981

  Brilakis, Emmanouil S ^a,b   Khera, Amit ^a   Saeed, Bilal ^a,b   Banerjee, Subhash ^a,b   McGuire, Darren K ^a   Murphy, Sabina A ^c   De Lemos, James A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; CALCIUM;

ADULT; AGED; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY ATHEROSCLEROSIS; ELECTRON BEAM TOMOGRAPHY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ADULT; AGED; AORTA, ABDOMINAL; AORTIC DISEASES; ATHEROSCLEROSIS; CALCINOSIS; CALCIUM; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SEX FACTORS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 57149115410     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.107359     Document Type: Article

References (18)

1. 2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 2007;14:3-11.
2. 2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006;113:1745-52.
3. 2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 2005;25:216-21.
4. Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 2004;93:1473-80.
5. 2 levels: observations from the Dallas Heart Study. Atherosclerosis 2007;199:110-5.
6. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002;156:871-81.
7. Jain T, Peshock R, McGuire DK, Willett D, Yu Z, Vega GL, et al. African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J Am Coll Cardiol 2004;44:1011-7.
8. Jaffer FA, O'Donnell CJ, Larson MG, Chan SK, Kissinger KV, Kupka MJ, et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2002;22:849-54.
9. Persson M, Nilsson JA, Nelson JJ, Hedblad B, Berglund G. The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 2007;190:388-96.
10. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150:413-9.
11. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 2003;44:1381-6.
12. 2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005;26:137-44.
13. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005;111:980-7.
14. 2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 2005;182:181-8.
15. 2 and coronary calcification. The Rotterdam Coronary Calcification Study. Atherosclerosis 2007;191:377-83.
16. 2 with coronary calcification among American and Japanese men. J Epidemiol 2007;17:179-85.
17. 2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007;82:159-65.
18. Khera A, de Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA, et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 2006;113:38-43.